Orforglipron vs Liraglutide | Research Comparison | QSC

Orforglipron vs Liraglutide: Research Comparison

Mechanism, clinical data, and research applications compared

Shop Both Compounds at QSC →

Factor Orforglipron Liraglutide
Drug Class Non-peptide GLP-1R agonist GLP-1R monoagonist (daily injectable)
Route Oral once-daily SC weekly / oral
Phase 2/3 Result −14.7% (36 wks)* ~8% weight loss
At QSC ✓ In Stock ✓ In Stock
Research Analysis: Orforglipron: oral, once-daily, superior Phase 2 efficacy. Liraglutide: approved, daily injection.
Research Use Only: All QSC products for in vitro laboratory research only. Not for human use.
Peptides
Orals
Oils
Search
Contact